Enterprise Value
1.431B
Cash
297.7M
Avg Qtr Burn
N/A
Short % of Float
12.87%
Insider Ownership
5.02%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Trokendi XR® (topiramate) Details Prophylaxis of migraine | Approved Quarterly sales | |
APOKYN® (apomorphine hydrochloride injection) Details Advanced Parkinson’s disease (PD) | Approved Quarterly sales | |
Gocovri (Amantadine) Details Dyskinesia (Parkinson's disease) | Approved Quarterly sales | |
Namzaric Details Alzheimer's Dementia | Approved Quarterly sales | |
Osmolex ER (amantadine) Details PD (Parkinson's Disease) | Approved Quarterly sales | |
MYOBLOC® (rimabotulinumtoxinB) Details Cervical Dystonia Sialorrhea | Approved Quarterly sales | |
XADAGO (safinamide) Details Parkinson's disease | Approved Quarterly sales | |
Oxtellar XR® (oxcarbazepine) Details Epilepsy | Approved Quarterly sales | |
Qelbree (viloxazine hydrochloride) Details Mental health, Attention deficit hyperactivity disorder | Approved Quarterly sales | |
Gocovri (Amantadine) Details Parkinson's disease for OFF episodes | Approved Quarterly sales | |
SPN-830 (apomorphine infusion device) Details Parkinson's disease, Brain disease | NDA Resubmission | |
SPN-820/821 Details Treatment Resistant Depression, Mental health, Major depressive disorder | Phase 2b Data readout | |
SPN-817 Details Epilepsy | Phase 2a Data readout |